Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression

Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression

Background: Dual antiretroviral regimens are attractive options to optimize the combination antiretroviral therapy in light of potential toxicities with long-term cumulative exposure to nucleos(t)ide reverse-transcriptase inhibitors (NRTIs). Methods: In this retrospective observational study, we inc...

Full description

Bibliographic Details
Main Authors:	Tung-Che Hung, Guan-Jhou Chen, Shu-Hsing Cheng, Jhen-Hong Chen, Jheng-Lun Wei, Chien-Yu Cheng, Chien-Ching Hung
Format:	Article
Language:	English
Published:	Elsevier 2019-12-01
Series:	Journal of Microbiology, Immunology and Infection
Online Access:	http://www.sciencedirect.com/science/article/pii/S1684118219300866

Similar Items

Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review
by: Tatevik Balayan, et al.
Published: (2017-01-01)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
by: Ruxandra-Cristina Marin, et al.
Published: (2021-03-01)

Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
by: Takeshi Nishijima, et al.
Published: (2013-01-01)

Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?
by: Yohei Hamada, et al.
Published: (2013-01-01)

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.
by: Pierre Gantner, et al.
Published: (2016-01-01)

Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR
by: Christina M. Wyatt, et al.
Published: (2020-05-01)

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks
by: Squires KE, et al.
Published: (2017-03-01)

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.
by: Luis F López-Cortés, et al.
Published: (2016-01-01)

Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.
by: Alexandra U Scherrer, et al.
Published: (2012-01-01)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
by: Spagnuolo V, et al.
Published: (2019-01-01)

The Effectiveness of Hydroxychloroquine Versus Hydroxychloroquine Plus Lopinavir/Ritonavir Therapy in SARSCoV- 2 Pneumonia
by: Ayşe BATIREL, et al.
Published: (2021-12-01)

Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
by: Alexandra U. Scherrer, et al.
Published: (2013-01-01)

Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens.
by: Alexandra U. Scherrer, et al.
Published: (2013-01-01)

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
by: Yan-Ming Zeng, et al.
Published: (2020-05-01)

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT
by: Ross Lisa L, et al.
Published: (2008-03-01)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
by: Tony Antoniou, et al.
Published: (2017-04-01)

Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort.
by: Antonella d'Arminio Monforte, et al.
Published: (2016-01-01)

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
by: Eva Agnes Odongpiny Laker, et al.
Published: (2019-03-01)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
by: George W Rutherford, et al.
Published: (2016-01-01)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
by: Amedeo F. Capetti, et al.
Published: (2017-09-01)

Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
by: Elżbieta Jabłonowska, et al.
Published: (2019-01-01)

Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus-infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitor
by: Pierangelo Chinello, et al.
Published: (2015-03-01)

Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population
by: Rusconi Stefano, et al.
Published: (2012-08-01)

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice
by: Alberto Borghetti, et al.
Published: (2019-01-01)

Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir).
by: Kathleen M S E Reyskens, et al.
Published: (2013-01-01)

A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
by: Massimiliano Lanzafame, et al.

A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
by: Massimiliano Lanzafame, MD, et al.
Published: (2011-09-01)

Ritonavir Inhibits NF-AT Activation Through Effects on the PI-3 Kinase/Akt Pathway
by: Reitz Marvin, et al.
Published: (2005-12-01)

Ritonavir inhibits NF-AT activation through modulation of the PI-3 kinase/Akt Ppathway
by: Weichold Frank, et al.
Published: (2006-12-01)

No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
by: Yin-Qiu Huang, et al.
Published: (2020-07-01)

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
by: Claudio Ucciferri, et al.
Published: (2016-07-01)

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
by: Pei-Ying Wu, et al.
Published: (2017-01-01)

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
by: Tasker Sybil, et al.
Published: (2009-06-01)

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
by: Catherine Orrell, et al.
Published: (2015-01-01)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
by: Kathleen M. S. E. Reyskens, et al.
Published: (2013-01-01)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir).
by: Kathleen M. S. E. Reyskens, et al.
Published: (2013-01-01)

The maladaptive effects of HIV protease inhibitors (Lopinavir/Ritonavir) on the rat heart.
by: Reyskens, Kathleen Maria Simone Elise
Published: (2013)

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
by: Anna Maria Geretti, et al.
Published: (2015-01-01)

Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study
by: Sung-Hsi Huang, et al.
Published: (2020-02-01)

Dalitz plot analysis of B[superscript plus or minus]-->pi[superscript plus or minus]pi[superscript plus or minus]pi[superscript minus over plus] decays
by: Zhao, M., et al.
Published: (2010)